Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients

201860 citationsJournal Article

Authors

Yasuo Oshima · The University of Tokyo

Tetsuya Tanimoto · Jyoban Hospital

Koichiro Yuji · The University of Tokyo

Arinobu Tojo · The University of Tokyo

Abstract

The reporting proportion of PML was relatively higher in natalizumab followed by fingolimod, dimethyl fumarate and rituximab. Other characteristics of PML associated with DMDs, including the time to onset and differences in reporting among countries, are described.

Topics & Keywords

Polyomavirus and related diseases Plant Disease Resistance and Genetics Plant Virus Research Studies

UN Sustainable Development Goals

Partnerships for the goals

Publication Details

Published in: Multiple Sclerosis Journal

Volume 25, Issue 8, pp. 1141-1149

DOI: 10.1177/1352458518786075

Field-Weighted Citation Impact: 2.92